The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

SNIPR Biome receives up to €20 million European backing to advance therapies AMR
Finance

SNIPR Biome receives up to €20 million European backing to advance therapies AMR

DEC 10, 2024
UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies
Finance

UCalgary startup Taylored Biotherapeutics to commercialize psychobiotic therapies

DEC 2, 2024
A new simple and effective tool that recommends the best possible phage cocktail for a given patient
Infectious Disease & AMR

A new simple and effective tool that recommends the best possible phage cocktail for a given patient

NOV 28, 2024
Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science
Finance

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science

NOV 19, 2024
Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation
Finance

Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation

NOV 19, 2024
Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D
Editor's Choice

Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D

NOV 15, 2024
Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive
Pharma & Human Health

Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive

NOV 12, 2024
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
Pharma & Human Health

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis

NOV 11, 2024
Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013
Oncology

Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013

NOV 8, 2024
Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies
Pharma & Human Health

Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies

OCT 24, 2024
Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims
Biotics and Supplements

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims

OCT 22, 2024